Get the Stockscreener App
13.87
3.12%
0.42
After Hours:
13.88
0.01
+0.07%
Overview
News
Price History
Option Chain
Why RDY Down?
Discussions
Forecast
Stock Split
Dividend History
Dr Reddys Laboratories Ltd Adr stock is traded at $13.87, with a volume of 1.77M.
It is up +3.12% in the last 24 hours and down -5.00% over the past month.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
See More
Previous Close:
$13.45
Open:
$13.85
24h Volume:
1.77M
Relative Volume:
0.95
Market Cap:
$11.55B
Revenue:
$3.97B
Net Income/Loss:
$644.90M
P/E Ratio:
17.80
EPS:
0.7794
Net Cash Flow:
$90.19M
1W Performance:
+0.07%
1M Performance:
-5.00%
6M Performance:
-2.05%
1Y Performance:
+3.12%
1-Day Range:
$13.79
$13.97
1-Week Range:
$13.40
$14.31
52-Week Range:
$12.26
$16.17
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Compare RDY vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
13.87 | 11.20B | 3.97B | 644.90M | 90.19M | 0.7794 |
TAK
Takeda Pharmaceutical Co Adr
|
18.29 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.71 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.74 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.46 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
541.60 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Upgrade | HSBC Securities | Hold → Buy |
| Dec-19-24 | Downgrade | Nomura | Buy → Neutral |
| Jan-11-24 | Downgrade | Jefferies | Buy → Underperform |
| Aug-29-23 | Downgrade | HSBC Securities | Buy → Hold |
| May-18-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-17-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-30-23 | Initiated | JP Morgan | Underweight |
| Nov-14-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-03-22 | Resumed | BofA Securities | Neutral |
| Jul-27-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Feb-02-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-18-20 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-18-20 | Upgrade | Investec | Sell → Hold |
| Jan-28-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-27-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-09-20 | Upgrade | Citigroup | Sell → Buy |
| Nov-04-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Sep-04-19 | Upgrade | Credit Suisse | Underperform → Outperform |
| Jul-01-19 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-20-19 | Initiated | Deutsche Bank | Hold |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-20-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-19-19 | Upgrade | CLSA | Outperform → Buy |
| Jan-17-19 | Downgrade | Citigroup | Neutral → Sell |
| Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-31-17 | Upgrade | CLSA | Underperform → Outperform |
| Jul-28-17 | Downgrade | CLSA | Underperform → Sell |
| Jul-27-16 | Downgrade | HSBC Securities | Hold → Reduce |
| Jul-27-16 | Downgrade | Jefferies | Hold → Underperform |
| Feb-10-16 | Upgrade | Credit Agricole | Underperform → Buy |
| Nov-10-15 | Downgrade | Citigroup | Buy → Neutral |
View All
Dr Reddys Laboratories Ltd Adr Stock (RDY) Latest News
Morgan Stanley Upgraded, Tyson Foods Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply - Benzinga
RDY Stock Price, Quote & Chart | DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - ChartMill
Dr. Reddy's Laboratories Ltd Stock Faces Analyst Downgrade Despite Strong Valuation—What European - AD HOC NEWS
Dr. Reddy’s Allots New ESOP Shares, Slightly Increases Equity Capital - TipRanks
Dr. Reddy’s (NYSE: RDY) allots 10,275 ESOP shares to employees - Stock Titan
Dr. Reddy's Laboratories Announces Special Window for Physical Share Transfer Re-lodgement - scanx.trade
Dr. Reddy's Laboratories Allots 10,275 Equity Shares Under Employee Stock Options Scheme - scanx.trade
Dr. Reddy’s Laboratories issues 10,275 equity shares under stock options scheme - Business Upturn
Dr Reddy's ADR Slumps 10% After Bid To Launch Weight-Loss Drug In Canada Hits Regulatory Hurdle - MSN
Mercurity Fintech Holding Inc ADR share price - Mint
Mitsubishi UFJ Financial Group Inc ADR share price - Mint
3 Generic Drug Stocks to Watch Despite Industry Headwinds - The Globe and Mail
DR. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch GARP Investment Strategy - ChartMill
Dr. Reddy's Laboratories Receives SEC Letter Concluding Investigation Without Enforcement Action - scanx.trade
Dr. Reddy’s Stock Pops on US Launch Momentum: Buy the Breakout? - AD HOC NEWS
Toll Brothers Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy's Laboratories Allots 12,665 Equity Shares Under Employee Stock Option Schemes - scanx.trade
Dr. Reddy’s Allots 12,665 ESOP Shares, Nudging Up Equity Capital - TipRanks
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Investment Test - ChartMill
US-India Trade Deal: Indian ADRs Jump Up To 6.75%; Sensex & Nifty Set For Rally - samco.in
Dr. Reddy’s Labs ADR earnings beat by $14.36, revenue topped estimates - Investing.com Australia
Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y - Finviz
Dr. Reddy’s Strong Base Business, Aided by Partnerships and New Launches, Offsets North America Drag - Morningstar
Earnings call transcript: Dr. Reddy’s Q3 2026 sees revenue growth, stock dips By Investing.com - Investing.com India
Earnings call transcript: Dr. Reddy’s Q3 2026 sees revenue growth, stock dips - Investing.com
Infosys ADR stock jumps over 10% on Wall Street after IT major revises revenue guidance for FY2026 — Details here - Mint
Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32 - Finviz
Dr. Reddy’s Labs ADR: Quiet Rally, Firm Fundamentals – Is RDY Still Undervalued? - AD HOC NEWS
HDFC Bank share price drops almost 4% in 2 days after Q3FY26 business update - Mint
Infosys ADR Surges 15% Suddenly! Expert Feroze Azeez Reveals The Shocking Derivative Secret! - Whalesbook
Infosys trading: Infosys ADR 40% spike traced to data error, algo trading, says report - Business Today
What does Infosys ADR stock rally on the NYSE mean for Infosys shares on the NSE, BSE? - livemint.com
Infosys ADR stock jumps over 56% over strong volumes on US stock market today — Details here - livemint.com
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Screens - ChartMill
BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight - Finviz
Validea's Top Health Care Stocks Based On Peter Lynch12/15/2025 - Nasdaq
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch - Sahm
Asian Equities Traded in the US as ADRs Fall in Thursday Trading - 富途牛牛
Kelkar & Mehta: Justice is a constitutional promise: Uphold it by giving alternative dispute resolution a chance - Mint
Dr Reddys Share Price Highlights: Dr. Reddys Stock Price History - The Economic Times
Asian ADRs Nudge Higher As Tech And Pets Take The Lead - Finimize
Arrowpoint Investment Partners Singapore Pte. Ltd. Acquires New Shares in Full Truck Alliance Co. Ltd. Sponsored ADR $YMM - Defense World
Asian ADRs Dip In The US As Volatility Continues - Finimize
Asian ADRs Kick Off The Week With Broad Gains - Finimize
Is Zoetis Stock Underperforming the Dow? - Barchart.com
Dr Reddys Laboratories Ltd Adr Stock (RDY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
2.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):